PaperRed blood cells as delivery system for recombinant HSV-1 glycoprotein B: immunogenicity and protection in mice
References (26)
Challenges and progress in developing herpesvirus vaccines
TIB Tech.
(1995)- et al.
Efficacy of HSV-1 ISCOM vaccine in the guinea-pig model of HSV-2 infection
Vaccine
(1991) - et al.
Native herpes simplex virus glycoprotein D vaccine: immunogenicity and protection in animal models
Vaccine
(1991) - et al.
Liposome-formulated interleukin-2 as an adjuvant of recombinant HSV glycoprotein gD for the treatment of recurrent genital HSV-2 in guinea-pigs
Vaccine
(1992) - et al.
Placebo-controlled trial of vaccination with recominant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes
Lancet
(1994) - et al.
Immunogenicity in mice of tandem repeats of an epitope from herpes simplex gD protein when expressed by recombinant adenovirus vectors
Vaccine
(1993) - et al.
Development and evaluation of an ELISA using secreted recombinant glycoprotein B for determination of IgG antibody to herpes simplex virus
J. Virol. Meth.
(1991) - et al.
Constitutive expression in human cells of herpes simplex virus type 1 glycoprotein B gene cloned in an episomal eukaryotic vector
Virology
(1988) - et al.
Comparison of the effects of adjuvant doses on the quantitative and qualitative antibody response to selected antigens in New World squirrel monkeys Saimiri sciureus
Vaccine
(1993) - et al.
Immunological adjuvants: desiderable properties and side-effects
Mol. Immun.
(1991)
Herpes simplex virus vaccines as immunotherapeutic agents
Trends Microbiol.
Protection from herpes simplex virus type 1 lethal and latent infections by secreted recombinant glycoprotein B constitutively expressed in human cells with a BK virus episomal vector
J. Virol.
Cited by (30)
Blood cells as supercarrier systems for advanced drug delivery
2022, Medicine in Drug DiscoveryCitation Excerpt :The RBC-based DDSs also exhibit new applications in immunological and host defense therapies. For example, steroids and inhibitors can bind to RBCs to mitigate the inflammatory response and antigens can bind and deliver to defense cells to modulate the immune response [49,78–81]. Additionally, it was found that delivering antigens on the RBC surface to different cells could lead to diverse or even opposite immunological responses, and the determinant factors involved in these processes require further investigation [82–85].
Red blood cells: The metamorphosis of a neglected carrier into the natural mothership for artificial nanocarriers
2021, Advanced Drug Delivery ReviewsCitation Excerpt :Chemical conjugation of diverse polymers has been designed to mask blood group determinants in the quest for artificial universal donor blood as well as to improve the hydrodynamic properties of modified RBC and provide the flexible extended linkers for coupling of other cargoes. Candidate cargoes for surface loading RBCs include antigens and cytokines to modulate host defense [206], present ligands for vascular targeting of RBC cargoes [166,207,208], capture circulating pathological agents [209–211], or provide complement inhibitors to protect RBCs against pathological hemolysis, e.g., in the syndrome paroxysmal nocturnal hematuria (PNH) [212]. Due to relatively limited accessibility of extravascular compartments to the 5-µm RBC, this carrier seems most attractive for the agents whose targets are localized within the blood.
Tolerogenic vehicles of antigens in the antigen-specific immunotherapy for autoimmunity
2021, Journal of Drug Delivery Science and TechnologyNovel engineering: Biomimicking erythrocyte as a revolutionary platform for drugs and vaccines delivery
2021, European Journal of PharmacologyCitation Excerpt :A mouse model of HSV-I infection was used to analyze the immunotherapeutic potential of autologous RBCs coupled to the secretory form of HSV-I glycoprotein B (gBls) via a biotin-avidin-biotin bridge. In this study, gBls-RBC elicited an immunological response similar to that obtained with the same antigen in Freund's adjuvant known for HSV-1 lethal defect defense, with a high degree of protection against latent ganglion infection at doses 10 times lower than that obtained with the alum adjuvant (Chiarantini et al., 1997). As measured by ELISA and HSV-1 neutralization assays, gBls-RBC developed an anti-HSV antibody response comparable with or greater than that elicited by the same antigen in Freund's complete adjuvant, indicating that autologous RBCs coupled to gBls can provide an efficient and safe method for immunization against HSV infection.
Cell-mediated delivery of nanoparticles: Taking advantage of circulatory cells to target nanoparticles
2014, Journal of Controlled ReleaseCitation Excerpt :Building on the eventual blood clearance of red blood cells, antigens have been conjugated to the surface of red blood cells and delivered directly to immune cells for T-cell deletion applications [26]. Further, intraperitoneal injected HSV-1 glycoprotein B modified red blood cells have successfully been used for HSV-1 vaccinations, preventing lethal development of HSV-1 [27]. However, only recently have red blood cells been investigated for cellular hitchhiking applications [28–30].
Intranasal immunization in mice with non-ionic surfactants vesicles containing HSV immunogens: A preliminary study as possible vaccine against genital herpes
2013, International Journal of PharmaceuticsCitation Excerpt :The recombinant HSV glycoprotein B1s (gB1s) is a secreted protein with the transmembrane anchor sequence deleted and reconstructed with the extra-membrane and intra-cytoplasmic domains. Previous studies from our laboratory have reported on the nature of the immune response and the protection induced by prophylactic and therapeutic subunit vaccine based on gB1s (Cortesi et al., 2006; Manservigi et al., 2005; Caselli et al., 2001; Chiarantini et al., 1997; Manservigi et al., 1990). Moreover, we have shown that the polylysine rich peptide DTK (D-T-K-P-K-K-N-K-K-P-K-N-P-P-P) is able to induce neutralizing antibody and to protect rabbit against a lethal ocular challenge (Cortesi et al., 2006).